GlassScriptPhysician profile
Jairam Krishnamurthy
NPI 1932335007
$63,108.09
in general payments reported to CMS, 2019-2025
16 companies · $8,671 in 2025
The $8,671 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,795 · 2020: $4,290 · 2021: $8,282 · 2022: $13K · 2023: $14K · 2024: $6,022 · 2025: $8,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $945 · Food and Beverage: $697 · Grant: $350 · Education: $6.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,587.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $945.00 |
| Food and Beverage | $696.50 |
| Grant | $350.00 |
| Education | $6.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $32,436.27 | 2019-2025 | Enhertu, Truqap |
| Gilead Sciences, INC. | $9,344.50 | 2021-2022 | |
| Genzyme Corporation | $6,527.00 | 2020-2021 | |
| Pfizer INC. | $4,289.60 | 2021-2024 | |
| Abbvie INC. | $4,090.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,236.52 | 2025 | |
| Tersera Therapeutics LLC | $2,209.00 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $1,000.00 | 2020 | |
| Cepheid | $773.00 | 2020 | |
| Amneal Pharmaceuticals LLC | $128.00 | 2025 | |
| Ethicon US, LLC | $42.46 | 2024 | Enseal |
| Stemline Therapeutics INC. | $31.12 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairam Krishnamurthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.